0.0B, trading at HK$4.78 on the HKSE. This SniperIQ fundamentals page covers China Resources Pharmaceutical Group's valuation (P/E 6.7x, P/B 0.5x), profitability (net margin 1.5%), revenue (HK00.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
0.0B
P/E (TTM)6.7x
Net Margin1.5%
Revenue (FY25)HK
00.0B

Full research coverage

Frequently Asked Questions

What is China Resources Pharmaceutical Group's market cap?

China Resources Pharmaceutical Group (3320) has a market capitalization of approximately HK

0.0B, trading at HK$4.78 on the HKSE. Market cap moves with the live share price.

What is China Resources Pharmaceutical Group's P/E ratio?

China Resources Pharmaceutical Group's trailing twelve-month P/E ratio is 6.7x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is China Resources Pharmaceutical Group?

China Resources Pharmaceutical Group runs a net profit margin of 1.5%, a gross margin of 16.5%, and an operating margin of 4.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does China Resources Pharmaceutical Group generate?

China Resources Pharmaceutical Group reported revenue of HK

00.0B for fiscal year 2025, with net income of HK$4.5B and earnings per share (EPS) of 0.72. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does China Resources Pharmaceutical Group pay a dividend?

China Resources Pharmaceutical Group offers a trailing dividend yield of about 4.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is China Resources Pharmaceutical Group financially healthy?

China Resources Pharmaceutical Group carries a debt-to-equity ratio of 1.83x and a current ratio of 1.42x, with a market beta of -0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is China Resources Pharmaceutical Group a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Resources Pharmaceutical Group (3320) the key facts are: market cap HK

0.0B, P/E 6.7x, revenue HK00.0B, 52-week range 4.22-6.53. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track China Resources Pharmaceutical Group's full fundamentals live

Get China Resources Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.